AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00499343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Days +1 (375 mg/m\^2) and +8 (1000 mg/m\^2) given intravenously.
Study NCT00499343 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Apheresis
Description: Peripheral blood stem cell collection.
Study NCT02951793 — intervention group
Intervention type: OTHER
Intervention: AUDIT-C
Description: Patients or their proxy/closest family member(s) undergo a comprehensive questionnaire including AUDIT-C about his/her alcohol behavior during last year and will be categorized into two groups: Those with AUDIT-C>4 versus AUDIT-C of 4 or below.
Study NCT02951793 — intervention group
Intervention type: OTHER
Intervention: Smoking history
Description: Patients or their proxy/closest family member(s) undergo a comprehensive questionnaire including smoking history during last year and will be categorized into two groups: Current smoker versus ex- or never smoker (we also recorded smoking pack-years to distinguish heavy smokers)
Study NCT02951793 — intervention group
Intervention type: OTHER
Intervention: Prior psychotropic medication use
Description: Patients or their proxy/closest family member(s) undergo a comprehensive questionnaire including psychotropic medication use prior admission to ICU and will be categorized into two groups: Those who use psychotropic medication versus those who do not use psychotropic medication.
Study NCT04073342 — intervention group
Intervention type: GENETIC
Intervention: Gene expression of inflammatory mediator (Interleukin 8) and recognition receptor of Toll like receptor (TLR4).
Description: Ileal tissue from both group will be tested for gene expression of inflammatory mediator (Interleukin 8) and recognition receptor of Toll like receptor (TLR4).
Study NCT06182345 — intervention group
Intervention type: PROCEDURE
Intervention: spray skin
Description: autologous skin cell suspension combined with skin graft
Study NCT06182345 — intervention group
Intervention type: PROCEDURE
Intervention: skin graft
Description: skin graft
Study NCT02453061 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triheptanoin oil
Description: Triheptanoin oil orally administered at 1g/kg/day
Study NCT02453061 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Safflower oil orally administered at 1g/kg/day
Study NCT03363347 — intervention group
Intervention type: DRUG
Intervention: Redifferentiation with retinoid acid
Description: In this retrospective study, patients with radioiodine refractory papillary thyroid cancer routinely received (clinical indication, no study medication was given) retinoid acid for redifferentiation prior to further course of radioiodine therapy.
Study NCT02677077 — intervention group
Intervention type: DRUG
Intervention: natalizumab
Description: Participants with RRMS receiving commercial natalizumab in Belgium and Czech Republic
Study NCT02557126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: URC102
Study NCT02557126 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03508947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WVE-210201
Description: WVE-210201 is a stereopure antisense oligonucleotide (ASO)
Study NCT03508947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sodium Chloride
Study NCT01543997 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind-Body Bridging Program
Description: Bridging aims to reduce the impact of negative thought patterns that contribute to stress in the body.
Study NCT01543997 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Education
Description: This intervention will provide educational lectures on disability, sleep hygiene, and current research on depression and nondirective, supportive discussions about these topics.
Study NCT01784523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Study NCT02453984 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 89Zr-MPDL-3280A-PET scans
Description: 89Zr-MPDL3280A tracer injection and 89Zr-MPDL-3280A-PET scans
Study NCT02605746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ceritinib 750mg
Study NCT00880022 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Flexitouch System
Description: ( 10 to 30 treatments depending on group assignment)
Study NCT00880022 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flexitouch System
Description: ( 10 to 30 treatments depending on group assignment)
Study NCT01620970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF03446962
Description: PF-03446962 will be administered in 1hr intravenously at a dose of 10 mg/Kg on day 1, then every 2 weeks until the evidence of disease progression or onset of unacceptable toxicity.
Study NCT00259428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronedarone (SR33589)
Description: oral administration
Study NCT00259428 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral administration
Study NCT01482299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: RAD001 (everolimus) 10 mg daily, orally without interruption.~1 cycle is equal to 4-week treatment. Treatment will be continued unless disease progression or intolerability.
Study NCT01642953 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Early recovery
Description: The patients are started on sips of water on the first postoperative day. If they are tolerable, a liquid diet is started on the second postoperative day, and a soft diet on a third postoperative day for them. We have a plan to discharge the patients on the fourth postoperative day if they exhibit at least three times soft diet without specific complaint and had normal clinical status and physical examination.
Study NCT01141166 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: nutritional and a rehabilitation plan.
Description: The intervention consisted of recommendations to the subject and their primary physician, and others providers, telephone calls of a nutritional and a rehabilitation plan.
Study NCT02261831 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: obese patients
Description: collection of blood sampling and biopsies
Study NCT02261831 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diabetic patients
Description: collection of blood sampling and biopsies
Study NCT03067545 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Step rate increase
Description: increase the step rate during running by 10% steps per minute
Study NCT03113747 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALLO-ASCs
Description: 1). Cryopreserved cell suspension of early passages of cultured allogeneic MSCs isolated from SVF obtained from lipoaspirate, a total of 10 mln. of cultured cells; 2).The TE-construct consisting of collagen- or fibrin-derived hydrogels and cells of early passages (up to P5) suspension of allogeneic cultured MSCs isolated from SVF obtained from lipoaspirate; Biological is applied by surface application over perforated (1:3) autologous skin graft following the covering with hypoadhesive bandage. This procedure is carried out twice - once simultaneously with a skin grafting procedure and 2-3 days following autodermoplasty, while bandaging.
Study NCT02689570 — intervention group
Intervention type: OTHER
Intervention: observational
Description: no interventions; observational study
Study NCT01173978 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Steroid hormone
Description: Steroid hormone: 37,5 mg of prednisolone; High energy diet: 130 % of recommended daily energy intake; Relative physical inactivity: no exercise and at least 8 hours of rest/day
Study NCT01173978 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No intervention
Study NCT00976690 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azathioprine OR Mesalazine
Description: Azathioprine : 2mg/kg/day Mesalazine : 4g/day
Study NCT01677299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EFB0027 (metformin delayed release)
Description: Comparison of enteric-coating to assess effect on PK
Study NCT02261831 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: patients free of obesity and diabetes
Description: collection of blood sampling and biopsies
Study NCT01677299 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EFB0026 (metformin immediate-release)
Description: Active comparator
Study NCT01677299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EFB0026 (metformin immediate-release)
Description: Active comparator
Study NCT02593383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adapalene + Clindamycin Hydrochloride
Description: 0.1% Adapalene + 1% Clindamycin Hydrochloride
Study NCT02593383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adapalene + Clindamycin Hydrochloride
Description: 0.1% Adapalene + 2% Clindamycin Hydrochloride
Study NCT02593383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adapalene + Clindamycin Hydrochloride
Description: 0.05% Adapalene + 0.5% Clindamycin Hydrochloride
Study NCT02593383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adapalene + Clindamycin Hydrochloride
Description: 0.05% Adapalene + 1% Clindamycin Hydrochloride
Study NCT02593383 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02838537 — intervention group
Intervention type: DRUG
Intervention: Exposure to Triptan
Study NCT02838537 — intervention group
Intervention type: DRUG
Intervention: Exposure to Ergot
Study NCT02007200 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02007200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soy Isoflavones
Description: Given PO
Study NCT02007200 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study NCT02422732 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Neuropsychological assessments
Description: IQ (WISC-IV)~Reading tests (reading accuracy, reading speed, reading comprehension and strategy):~Alouette, Lobrot, Odedys tests. Visuo-spatial skill (JLO, Thurston, CORSI tests) Attention (CPT 2, CBCL) Receptive oral language (EVIP)
Study NCT02261831 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: patients free type 2 diabetes
Description: collection of blood sampling and biopsies
Study NCT04653155 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy for insomnia
Description: Cognitive behavioural therapy for insomnia
Study NCT00450853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: granisetron
Description: Granisetron SC followed by granisetron IV
Study NCT02422732 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: morphological and functional MRI (fMRI)
Description: The fMRI will consider on the acquisition of a 3D anatomical sequence in T1 high resolution in axial slices of 1mm with an acquisition time of 10 min and a T2 sequence and a Flair to allow UBO location.
Study NCT02422732 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: genetic analysis
Description: Blood collection in 3 tubes (2 PAXgen® and 1 EDTA) and analysis to study the NF1 gene deletion.
Study NCT02922283 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IL2-PET scan
Description: All patients in this study will undergo a IL2 PET scan at baseline and week 6 of treatment with immunotherapy.
Study NCT02922283 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor biopsy
Description: A procedure to acquire tissue of a predetermined melanoma metastasis will be performed in all patients that participate in phase 2 of this study.
Study NCT02922283 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CT scan
Description: A CT scan of diagnostic quality will accompany all the PET scans and will additionally been made 12 and 16 weeks after start of immunotherapy to evaluate response to treatment.
Study NCT02922283 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy of non-target tissue
Description: A biopsy of skin and colon non-target tissue involved in an immune-related side effect is optional in patients that participate in phase 2 of this study.
Study NCT02140736 — intervention group
Intervention type: DRUG
Intervention: Epoetin biosimilar
Study NCT03723577 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fibrillar collagen powder dressing
Description: A powder-like fibrillar collagen microsponge composed of Type I porcine dermis collagen. The dressing is a currently marketed, cleared device in the United States, indicated for the management of full and partial thickness wounds: pressure ulcers, diabetic ulcers, caused by mixed vascular origin, venous ulcers, and several other wound types.
Study NCT02866669 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Practice Facilitation
Description: ractices that are randomized to the practice facilitation arm will work with a practice facilitator that will help practice staff for 15 months to make practice level changes to improve hypertension control. Practice facilitation is a highly customized, staged approach to helping a practice to implement process and structural changes to enhance the quality of care and improve patient and staff satisfaction
Study NCT02866669 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Coach
Description: Participants enrolled from practices that are randomized to the peer coach arm will be matched with peer advisors who will work with the participants for 12 months.
Study NCT02866669 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced usual care
Description: Practices in the usual enhanced care arm will receive a blood pressure medication algorithm developed using national guidelines and content experts on our study team. Practices will be provided the Joint National Committee (JNC) recommended protocol to measuring blood pressures. Practices will receive a laptop workstation that has access to the Patient Activated Learning System - an online education video system.
Study NCT02866669 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced usual care
Description: Practices in the usual enhanced care arm will receive a blood pressure medication algorithm developed using national guidelines and content experts on our study team. Practices will be provided the Joint National Committee (JNC) recommended protocol to measuring blood pressures. Practices will receive a laptop workstation that has access to the Patient Activated Learning System - an online education video system.
Study NCT02714712 — intervention group
Intervention type: DRUG
Intervention: Peginterferon alfa-2a
Description: Peginterferon alfa-2a 180μg plus daily oral weight-based ribavirin (1,000 mg for body weight 75 kg or less, 1,200 mg for body weight greater than 75 kg) for 24 or 48 weeks
Study NCT01437423 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TETRAXIM™: Combined adsorbed diphtheria, tetanus, acellular pertussis and enhanced inactivated polio
Description: 0.5 mL, Intramuscular at 2, 4, 6 months (Primary) or at 4 to 6 years (Booster) vaccination
Study NCT00907764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: regadenoson
Description: 400 ug, IV
Study NCT04303234 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Artinibsa
Description: local anaesthetic solution with a short latency time. Its high lipid solubility gives it better diffusion through soft tissues and bone and makes it highly effective for infiltrative techniques.Each ml contains 4%Articaine 1:100000.
Study NCT04303234 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Artpharma
Description: Its a special amide local anesthetic contain 4% articaine with epinephrine 1/200000 as a vasoconstrictor ,Contains only sulfite as a stabilizer (max 0.31 mg)
Study NCT01090297 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: S8 Spirit 2
Description: 3 types of Continuous Positive Airway Pressure (CPAP) device: S8 Spirit 2, Somnosmart 2, Remstar Auto.~These 3 types of CPAP can be set in both mode of pressure.
Study NCT01090297 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Somnosmart 2
Description: 3 types of Continuous Positive Airway Pressure (CPAP) device: S8 Spirit 2, Somnosmart 2, Remstar Auto.~These 3 types of CPAP can be set in both mode of pressure.
Study NCT01090297 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Remstar Auto
Description: 3 types of Continuous Positive Airway Pressure (CPAP) device: S8 Spirit 2, Somnosmart 2, Remstar Auto.~These 3 types of CPAP can be set in both mode of pressure.
Study NCT03334422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally
Study NCT03334422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally
Study NCT03920098 — intervention group
Intervention type: OTHER
Intervention: Nutrition and mental health during pregnancy
Description: Altered metabolic milieu is defined as a fasting glucose level >100 mg/dL at the first trimester of pregnancy by national guidelines. Altered metabolic milieu during the second trimester (24-28 weeks of pregnancy) is defined as a fasting glucose levels > 92 mg/dL and/or plasma glucose levels > 153 mg/dL two hours after load in the oral glucose tolerance test according to ADA guidelines or a fasting glucose >100 mg/dL and/or > 140 mg/dL two hours after load in the oral glucose tolerance test according to national guidelines. The COVID-19 pandemic is considered as a natural nutritional and mental health exposure.
Study NCT03835962 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuroCatch™ Platform
Description: NeuroCatch Platform™ consists of software and hardware that captures brain health information. The platform intends to provide a quick, portable and easy to use solution for the acquisition, display, analysis, storage, reporting and management of electroencephalograph (EEG) and event-related potential (ERP) information.
Study NCT05963009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: baxdrostat (formerly CIN-107) oral solution
Description: 5 mg single dose of baxdrostat given as either a solution or tablet in either the fed or fasted state, depending on the arm of the study
Study NCT04510298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP-624
Description: Oral Capsule
Study NCT04510298 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Capsule
Study NCT02417649 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1. The placebo will be administered for a period of three months. The first ten days of each month, one tablet per day will be given. The tablet will be melted under the tongue. After the ten day therapy, a twenty day of rest will be provided. Then the second and the third month the administration schedule will be identical.~2. Three months of rest, according to the indications, will be allowed.~3. A second cycle (the same as point 1.) will be performed~4. A second three month rest (according to point 2.) will be provided.
Study NCT03334422 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study NCT03304275 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tdap
Description: Randomized controlled trial of 2 strategies to provide adults with the Tdap vaccine
Study NCT03231137 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PRGF/ATV
Description: Atorvastatin (ATV) loaded on plasma rich in growth factor (PRGF) Derived Fibrin Scaffold
Study NCT03231137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATV gel
Description: Atorvastatin gel
Study NCT03231137 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRF
Description: Platelet rich fibrin
Study NCT03231137 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRGF
Description: plasma rich in growth factor
Study NCT02417649 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ismigen
Description: 1. The tablet will be administered for a period of three months. The first ten days of each month, one tablet per day will be given. The tablet will be melted under the tongue. After the ten day therapy, a twenty day of rest will be provided. Then the second and the third month the administration schedule will be identical.~2. Three months of rest, according to the indications, will be allowed.~3. A second cycle (the same as point 1.) will be performed~4. A second three month rest (according to point 2.) will be provided.
Study NCT03865953 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LAT8881
Description: LAT8881 oral capsule
Study NCT03865953 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral capsule
Study NCT01514851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate (BAY77-1931)
Study NCT00693485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 400 ug Brimonidine Implant
Description: 400 ug Brimonidine Tartrate Posterior Segment Drug Delivery system; Applicator System at Day 1 in study eye.
Study NCT00693485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 ug Brimonidine Implant
Description: 200 ug Brimonidine Tartrate Posterior Segment Drug Delivery system; Applicator System at Day 1 in study eye.
Study NCT00693485 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham (no implant)
Description: Sham Posterior Segment Drug Delivery system; Applicator System at Day 1 in study eye.